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Abstract Application of leukotriene B4 (LTB4) to nor-
mal human skin induces changes similar to those found
in psoriatic skin, and it has proved to be a useful model
for studying the pathogenesis and treatment of psoria-
sis. We studied the expression patterns of molecules
that have recently been shown to be altered in lesional
psoriatic skin, including the extracellular matrix pro-
tein tenascin (TN) and the basement membrane and
cell surface-associated heparan sulfate proteoglycans
(HSPGs). During 72-h the expression of these markers
was studied immunohistochemically and the expres-
sion of TN was correlated with epidermal proliferation
and influx of inflammatory cells. Following the peak
influx of polymorphonuclear leukocytes, a marked in-
crease in TN expression was noted in the papillary der-
mis 72 h after LTB4 application. The expression pat-
terns of basal membrane-associated epitopes of HSPG
remained unaltered, whereas the expression of cell sur-
face-associated HSPG disappeared 72 h after LTB4 ap-
plication. A significant correlation was found between
dermal TN expression and epidermal hyperprolifera-
tion, and between TN expression and the presence of
dermal T cells. These findings indicate that the model
of LTB4-induced acute cutaneous inflammation dis-
plays many characteristics of early psoriatic lesions
and could serve as a model to study some of the cell bi-
ological changes in this disease.
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Introduction
Epicutaneous application of the potent chemoattractant
leukotriene B4 (LTB4) results in a reproducible cutaneous
inflammatory response, initially dominated by an accu-
mulation of polymorphonuclear leukocytes (PMN) with a
maximum at 24 h, and followed by a dermal T-cell infil-
trated which is most pronounced after 72 h. Epidermal hy-
perproliferation occurs, reaching a maximum after 72–96 h.
These phenomena are dose dependent [1, 2]. Although
LTB4 is not likely to be the only or primarly pathogenetic
event in psoriasis [3], the morphologic changes in the skin
using the LTB4-model are a useful means of investigating
acute inflammation in vivo and partially mimic the hall-
marks of psoriatic skin lesions.
The extracellular matrix (ECM) plays an important
role in cell growth, differentiation and migration. It pro-
vides firmness, elasticity, and resilience to tissues. The
ECM is not inert but interacts with keratinocytes, inflam-
matory cells, cytokines and growth factors. Recently it
has been shown that some ECM molecules are altered in
lesional skin of psoriatic patients [4, 5], including tenascin
and the heparan sulfate proteoglycans (HSPGs).
The expression of the dermal glycoprotein tenascin is
limited in normal skin but profoundly increased in chronic
and subacute inflammatory disorders such as psoriasis,
acne, and alopecia areata [4, 6, 7]. It is also found in in-
creased amounts in epidermal tumors and in wound heal-
ing [8]. In acute inflammation, however, the expression of
tenascin has never been investigated.
In addition, the basal membrane (BM) and cell surface
associated HSPGs have been shown to be changed in pso-
riasis [5]. HSPGs play an important role in assembly of
the BM, bind growth factors and influence charge-depen-
dent transport of molecules. They consist of heparan sul-
fate (HS) side chains, which are covalently bound to a
core protein, and they are present in the BM of the epi-
dermis, cell membranes and blood vessels [9]. In psoria-
sis, cell surface-associated HSPGs are absent, whereas
they are clearly found in the epidermis of normal skin [5].
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Furthermore, the pattern of basal membrane-associated
HSPGs are also altered in psoriasis: the high-sulfated do-
main of the HS side chain is absent in the tips of the der-
mal papillae [5].
In this study, the expression of the ECM proteins
tenascin and basal and cell surface-associated HSPGs was
studied immunohistochemically in normal human skin af-
ter epicutaneous application of LTB4 over 72 h. In order to
find out whether tenascin expression is most related to
proliferation or differentiation in this model of acute in-
flammation, its expression in relation to epidermal prolif-
eration and influx of inflammatory cells (PMNs and T
lymphocytes) was investigated. This study indicated that
the application of LTB4 induced many changes in ECM
molecules that can also be found in early psoriatic lesions.
Materials and methods
Volunteers and biopsies
A group of 16 healthy male volunteers (mean age 27 years) with-
out signs or history of skin disorders participated in this study. Be-
fore the application of LTB4, a 4-mm punch biopsy was taken un-
der local anaesthesia, to assess the histology of the unchallenged
skin.
Aliquots of 100 ng LTB4 (Paesel, Frankfurt, Germany) dis-
solved in 10 µl ethanol were applied to the skin of the upper part
of the back of the volunteers through a plastic cylinder (6.5 mm di-
ameter) and the ethanol was evaporated under a stream of nitrogen.
The test sites were covered with impermeable dressing (Silver
Patch, van der Bend, Brielle, The Netherlands) held in place with
Leukosilk tape (Beiersdorf, Hamburg, Germany).
Further 4-mm punch biopsies were taken 24 and 72 h after
LTB4 application under local anaesthesia. The biopsies were washed
in phosphate-buffered saline (PBS; NPBI, Emmer-Compascuum,
The Netherlands), embedded in Tissue Tek OCT compound (Miles
Scientific, Naperville, Ill.), snap-frozen in liquid nitrogen and
stored at –80°C. They were sectioned at 7 µm and fixed for 10 min
in acetone/ether (60/40 vol%) for MIB-1, or in acetone (0°C) for
staining with the other antibodies and again stored at –80°C until
use.
Permission to conduct this study was obtained from the local
Ethics Committee of the University Hospital Nijmegen. Informed
consent was given by all subjects in this study. All volunteers tol-
erated the applications of LTB4 well. After 24 h, slight erythema
was seen at the application sites.
Antibodies
For immunohistochemical staining of tenascin, the monoclonal an-
tibody (mAb) T2H5 was used (kindly provided by Dr. A. A. Ver-
straten, The Netherlands Cancer Institute, Amsterdam, The Nether-
lands). For immunohistochemical staining of HSPGs, three mAbs
were used: JM-72, JM-403, and JM-13 (J. vd Born, Department of
Nephrology, University Hospital Nijmegen). The production, char-
acterization and demonstration of specificity of these mAbs has
been carried out by van den Born et al. [10–13]. The mAb JM-72
is directed against the BM-associated HSPG core protein, JM-13
against the sulfated domains of the HS side chains and JM-403
against the unmodified/low-sulfated domains of the HS side chains.
To study inflammation, the mAbs T11, directed against T lympho-
cytes (anti-CD2; Dakopatts, Copenhagen, Denmark) and antielas-
tase against elastase present in PMN (Dakopatts) were used. The
mAb MIB-1 which detects the nuclear antigen Ki-67 present in the
late G1, S and G2 + M phases of the cell cycle was used as a marker
for proliferation (Immunotech, Marseille, France).
Immunohistochemical staining
For staining with the mAbs JM-72 (1 : 250 in PBS), JM-403 (1 :250),
T2H5 (1 :2000), MIB-1 (1 :50) and antielastase (1 :100) and indi-
rect peroxidase technique was used. After thawing at room tem-
perature for 30 min, slides were fixed again in acetone (0°C), or in
acetone/ether (60/40 vol%) for MIB staining, for 10 min. They were
washed in PBS and incubated for 1 h with the primary antibodies.
After washing twice in PBS the slides were incubated for 30 min
with a solution of peroxidase-conjugated rabbit antimouse immu-
noglobulins (RAM-Ig) 1 :50 (Dakopatts) in phosphate buffer con-
taining 5% human AB serum. After two further washes in PBS,
slides were stained in a solution of 3-amino-9-ethyl-carbazole (AEC)
in sodium acetate buffer containing 0.01% H2O2 for 10 min.
Staining with the mAb JM-13 was carried out using the Vec-
tastain Elite ABC kit (Vector Laboratories, Burlingame, Calif.).
Sections were preincubated for 20 min with 20% normal horse
serum and after removing the excess serum, sections were incu-
bated with an undiluted culture supernatant of the mAb JM-13 for
60 min. After two washing steps, sections were incubated for 30
min with a solution of horse antimouse immunoglobulins, diluted
1 :200 in PBS containing 1% bovine serum albumin. This was fol-
lowed by a washing step and incubation with Vectastain Elite
ABC reagent for 30 min. After two further washes in PBS, slides
were stained in a solution of AEC in sodium acetate buffer con-
taining 0.01% H2O2 for 10 min.
Staining with T11 was carried out using a peroxidase antiper-
oxidase technique (PAP). Slides were incubated with the primary
antibody (1 :100) for 60 min, washed twice in PBS and than incu-
bated with 1 :50 RAM-Ig (Dakopatts). After two more washes in
PBS, PAP complexes were added (Dakopatts). The incubation with
RAM-Ig and PAP was repeated and after two additional washes in
PBS and preincubation with sodium acetate buffer, pH 4.9, slides
were stained with AEC solution. All slides were counterstained
with Mayer’s hematoxylin (Sigma, St. Louis, Mo.) mounted in
glycerine gelatine (Sigma), and studied by light microscopy.
Histological examination
The distribution of the stainings was assessed by two independent
investigators. Tenascin expression in the dermis was assessed us-
ing an eight-point scale: 0 = no staining, 1 = sporadic staining in
the upper dermis adjacent to the BM of the dermoepidermal junc-
tion (DEJ), 2 = a patchy distribution in the upper dermis adjacent
to the BM, but not present in all dermal papillae, 3 = a patchy ex-
pression in the tips of all dermal papillae, but not continuous, 4 =
3 but extending more deeply into the dermis, 5 = a thin but contin-
uous layer adjacent to the BM, 6 = a continuous layer adjacent to
the BM and in the papillary dermis, 7 = staining extending into the
reticular dermis. Expression of HSPGs (JM-13, JM-403 and JM-
72) in the BM of the DEJ and the BM of blood vessels was ap-
praised using a three-point scale: 0 = staining not present, 1 = dis-
continuous staining, 2 = continuous staining. The expression of
cell surface-associated HSPGs (JM-403 in the epidermis) was as-
sessed using a four-point scale: 0 = no staining, 1 = sporadic stain-
ing, 2 = pronounced staining, 3 = complete staining. Epidermal
proliferation was measured by counting the number of MIB-1-pos-
itive nuclei per millimeter length of section. The density of PMN
and T lymphocytes was assessed in the epidermis and dermis using
seven-point scales: epidermis 0 = no positive cells observed, 1 =
sporadic staining, 2 = minimal presence, 3 = moderate presence, 
4 = moderate/pronounced presence, 5 = pronounced presence, 6 =
complete staining; dermis 0 = no positive cells, 1 = sporadic stain-
ing, 2 = 1–25% of infiltrate cells stained, 3 = 26–50%, 4 =
51–75%, 5 = 76–99%, 6 = 100%. The dermal infiltrate was subdi-
vided into perivascular staining and diffuse dermal staining.
Statistical analysis
For statistical analysis Student’s t-test was used. The chosen level
of significance was P ≤ 0.05.
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Results
Immunohistochemistry
Tenascin
In all specimens of unchallenged skin, tenascin expres-
sion was discontinuous, varying from sporadic to patchy,
in the papillary dermis (Fig. 1). Continuous staining for
tenascin was found adjacent to the BM of blood vessels,
eccrine sweat ducts and hair follicles. A slight decrease in
tenascin expression was seen 24 h after LTB4 application,
but after 72 h, a marked increase in tenascin was found 
(P = 0.089 and P = 0.0006, respectively). All dermal
papillae were intensely stained and the staining extended
into the papillary and reticular dermis (Fig. 2), and in 10
of 16 specimen this distribution was continuous.
HSPGs
In normal skin, staining with JM-403, directed against the
low-sulfated domains of the HS side chains, showed a ke-
ratinocyte surface-associated pattern (Fig. 3). After 24 h
of LTB4 exposure, however, the staining became less
prominent (P < 0.0001) and after 72 h the expression var-
ied from sporadical to completely absent (P < 0.0001, Fig.
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Fig.1 Tenascin expression in normal human skin (× 200)
Fig.2 Tenascin expression in normal skin 72 h after topical LTB4
application (× 200)
Fig.3 HSPG staining in normal skin using mAb JM-403 directed
against the low-sulfated side chains (× 200)
Fig.4 HSPG staining in normal skin 72 h after LTB4 application
(JM-403, × 200)
4). In addition, JM-403 staining was seen in the BM of the
epidermis and blood vessels where no differences were
seen between challenged and unchallenged skin.
Neither JM-72 (directed against the core protein of
HSPG) nor JM-13, (directed against the highly sulfated
domains of the HS side chains) showed differences in ex-
pression between unchallenged and challenged skin 24
and 72 h after LTB4 application. The distribution of JM-
72 was continuous and restricted to the BM of the DEJ
and blood vessels. JM-13 staining of the BM of the DEJ
was comparable to JM-72 staining but the BM of blood
vessels did not stain before or after application of LTB4.
Semiquantitative data on immunohistochemical stainings
are summarized in Table 1.
Correlation of tenascin expression 
with epidermal proliferation and inflammation
Proliferation
The number of MIB-positive nuclei changed after LTB4
challenge: following a reduction after 24 h (P < 0.0001),
a marked increase was observed at 72 h (P = 0.001). Fig-
ure 5a shows that the changes in the expression of
tenascin were correlated significantly with the numbers of
MIB-stained nuclei in the epidermis (r = 0.642, P <
0.0001).
Inflammation
In epidermal and dermal skin compartments a repro-
ducible accumulation of PMNs was seen as assessed by
staining for leukocyte elastase. Maximal presence of
PMNs was seen 24 h after LTB4 exposure (P < 0.0001) in
the dermis in a perivascular and diffuse pattern, as well as
in the epidermis. At 72 h there were substantially fewer
PMNs in both compartments (P < 0.0001) but they were
still present. Only a borderline significant correlation was
found between tenascin expression and epidermal PMNs
(r = 0.27, P = 0.06). No correlations were found between
the presence of PMNs in the dermis and tenascin expres-
sion.
In contrast to the slight increase in epidermal T lym-
phocytes, dermal diffuse and perivascular T lymphocytes
showed a marked increase in number, with a maximum at
72 h (P < 0.0001). The expression of dermal T lympho-
cytes (perivascular and diffuse) correlated significantly
with tenascin expression (r = 0.45, P = 0.001 and r = 0.48,
P = 0.0004, respectively). This is shown in the Figures 5
b, c. No significant correlation was found between epider-
mal T lymphocytes and tenascin expression.
Discussion
In this study, the expression of the ECM molecules tenascin
and HSPG in acutely inflamed skin after topical LTB4 ap-
plication was investigated and related to epidermal prolif-
eration and cutaneous inflammation. A significant in-
crease in tenascin expression was found as early as 72 h
after LTB4 challenge. The staining pattern was similar to
that found in psoriasis. The increase in tenascin correlated
with epidermal proliferation, the presence of T lympho-
cytes in the dermis and the influx of epidermal PMN.
Tenascin is known to be increased in conditions of in-
creased epidermal proliferation including wound healing,
tape stripping and hyperproliferative skin diseases such as
psoriasis and skin carcinomas [4, 14, 15]. It is thought that
the production of tenascin might be stimulated by the pro-
liferating epidermis [15]. On the other hand, an increased
expression of tenascin has been reported in skin disorders
characterized by inflammation (alopecia areata, acne), in
areas where many inflammatory cells are present. It has
been postulated that cytokines derived from inflammatory
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Table 1 Results of immuno-
histochemical stainings (means
± SEM, n = 16)
0 h 24 h 72 h
Tenascin 2.69 (± 0.34) 2.25 (± 0.30) 4.63 (± 0.39)
HSPG core DEJ 2.00 (± 0.00) 2.00 (± 0.00) 2.00 (± 0.00)
HSPG core blood vessels 2.00 (± 0.00) 2.00 (± 0.00) 2.00 (± 0.00)
HSPG core epidermis 0.00 (± 0.00) 0.00 (± 0.00) 0.00 (± 0.00)
HS low-sulfated DEJ 2.00 (± 0.00) 2.00 (± 0.00) 2.00 (± 0.00)
HS low-sulfated blood vessels 2.00 (± 0.00) 2.00 (± 0.00) 2.00 (± 0.00)
HS low-sulfated epidermis 2.00 (± 0.20) 0.88 (± 0.13) 0.31 (± 0.12)
HS highly sulfated DEJ 2.00 (± 0.00) 2.00 (± 0.00) 2.00 (± 0.00)
HS highly sulfated blood vessels 2.00 (± 0.00) 2.00 (± 0.00) 2.00 (± 0.00)
HS highly sulfated epidermis 0.00 (± 0.00) 0.00 (± 0.00) 0.00 (± 0.00)
Ki-67-positive nuclei 62.1 (± 3.99) 23.2 (± 3.54) 201 (± 33.8)
Elastase, epidermis 0.00 (± 0.00) 3.78 (± 0.23) 1.63 (± 0.21)
Elastase, diffuse dermis 0.00 (± 0.00) 4.00 (± 0.18) 2.41 (± 0.30)
Elastase, perivascular 0.13 (± 0.09) 3.19 (± 0.19) 1.94 (± 0.12)
T lymphocytes, epidermis 0.97 (± 0.16) 1.44 (± 0.18) 1.50 (± 0.13)
T lymphocytes, diffuse dermis 1.06 (± 0.11) 1.69 (± 0.15) 2.34 (± 0.16)
T lymphocytes, perivascular 2.09 (± 0.07) 2.66 (± 0.20) 3.53 (± 0.26)
infiltrate may regulate tenascin synthesis [6, 7]. In addi-
tion, tenascin inhibits monocyte adhesion to the ECM and
alters the adhesion properties of T cells in vitro, which
may be due to abrogation of an accessory cell function at
an early stage of the interaction between antigen-present-
ing cells and T cells [16], and may therefore have antiin-
flammatory activity. Furthermore, tenascin is elevated
during acute phase responses [17]. In this model, in which
actue inflammation can be investigated, tenascin expres-
sion correlated best with the expression of MIB-1, a marker
for proliferation.
A significant alteration in cell surface-associated HSPG
expression was found in normal skin after LTB4 applica-
tion. The pattern of cell membrane-associated staining
present in normal epidermis after staining with JM-403
disappeared 72 h after LTB4 application. In psoriasis, this
cell membrane-associated staining is also absent, in con-
trast to uninvolved psoriatic and normal skin, suggesting a
comparable mechanism behind the changed JM-403 stain-
ing in psoriasis and the LTB4 skin model. An influx of in-
flammatory cells in the dermis and epidermis may influ-
ence the expression of cell membrane-associated HSPGs.
In acute irritant dermatitis, however, an increase in the
concentration of HS occurs in normal skin and psoriatic
skin [18], as determined using glycosaminoglycans elec-
trophoresis of skin biopsies. Staining with JM-403 showed
a continuous staining in the DEJ of normal skin both be-
fore and 72 h after LTB4 application.
Staining of the core protein of HSPG did not show any
changes in acute LTB4-induced inflammation. Previous
studies on LTB4-challenged skin have indicated degrada-
tion of BM components by neutrophil elastase and ultra-
structural damage of the BM [1, 19]. This does not neces-
sarily imply, that the epitope of the large core protein of
HSPG, stained by JM-72, disappears. It can be concluded
that the core protein of HSPG, one of the major con-
stituents of the BM, remains virtually unaffected.
Staining with JM-13, against the high-sulfated parts of
the HSPG side chains, did not change after LTB4 applica-
tion. In psoriasis, however, loss of staining of JM-13 has
been found in the tips of the dermal papillae [5], where
PMNs are moving from the tips of the dermal papillae
into the epidermis and are known to release elastase and
free radicals. Degradation of the DEJ by proteolytic en-
zymes from human skin and human PMNs has been de-
scribed [20–22]. Furthermore, Diamond et al. have de-
scribed a direct interaction between the leukocyte integrin
Mac-1 and HSPGs [23]. Mac-1 is the main integrin in-
volved in adhesion of PMN. It has thus been speculated
that in psoriasis the loss of side chain staining of HSPG
could be due to cleavage of the JM-13 epitope by prote-
olytic enzymes. In the LTB4 model however, migrating
PMNs did not cause visible cleavage of the JM-13 epitope
during 72 h. In this study, staining of the dermal blood
vessels was unaltered, although the loss of HSPGs has
been previously reported in endothelial cells caused by
PMN-derived proteases [24].
In conclusion, pronounced changes in the dermoepi-
dermal interface were found in acute LTB4-induced in-
flammation. An increased tenascin expression and a re-
duction in keratinocyte-associated HSPG staining in the
epidermis were detected. Correlations with epidermal pro-
liferation as well as cutaneous inflammation were found,
but the correlation with proliferation of the epidermis was
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Fig. 5a–c Correlations between: a numbers of MIB-stained nuclei
and tenascin expression (r = 0.64), b expression of dermal perivas-
cular T lymphocytes and tenascin expression (r = 0.45), c expres-
sion of dermal diffuse T lymphocytes and tenascin expression (r =
0.48)
a
c
b
most pronounced. The findings indicate that the model of
LTB4-induced acute cutaneous inflammation displays
many characteristics of the early psoriatic lesion and
could serve as a model for the study of some of the cell bi-
ological changes in this disease.
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